The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Open accessAbstract
Purpose: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemotherapy in patients with refractory solid tumors. Patients and Methods: In part 1, patients received a single dose of AZD1775 followed by 14 days of observation. In part 2, patients received AZD1775 as a single dose (part 2A) or as five twice per day doses or two once per day doses (part 2B) in combination with one of the following chemotherapy agents: gemcitabine (1,000 mg/m 2), cisplatin (75 mg/m 2), or carboplatin (area under the curve, 5 mg/mL⋅min). Skin biopsies were collected for pharmacodynamic assessments. TP53 status was determined retrospectively in archival tumor tissue. Results: Two hundred two patients were enrolled onto the study, including nine patients in part 1, 43 in part 2A (including eight rollover patients from part 1), and 158 in part 2B. AZD1775 monotherapy given as single dose was well tolerated, and the maximum-tolerated dose was not reached. In the combination regimens, the most common adverse events consisted of fatigue, nausea and vomiting, diarrhea, and hematologic toxicity. The maximum-tolerated doses and biologically effective doses were established for each combination. Target engagement, as a predefined 50% pCDK1 reduction in surrogate tissue, was observed in combination with cisplatin and carboplatin. Of 176 patients evaluable for efficacy, 94 (53%) had stable disease as best response, and 17 (10%) achieved a partial response. The response rate in TP53-mutated patients (n = 19) was 21% compared with 12% in TP53 wild-type patients (n = 33). Conclusion: AZD1775 was safe and tolerable as a single agent and in combination with chemotherapy at doses associated with target engagement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2
Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M., & Beach, D. (1991) · Cell · doi:10.1016/0092-8674(91)90266-2 · Cited by 683
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Coleman, T. R., & Dunphy, W. G. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90060-4 · Cited by 414
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Self-citationFission yeast p107wee1 mitotic inhibitor is a tyrosine/serine kinase
Featherstone, C., & Russell, P. (1991) · Nature · doi:10.1038/349808a0 · Cited by 335
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Self-citationDo, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Self-citationBeck, H., Nähse-Kumpf, V., Larsen, M. S. Y., O'Hanlon, K. A., Patzke, S., Holmberg, C., Mejlvang, J., Groth, A., Nielsen, O., Syljuåsen, R. G., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00412-12 · Cited by 306
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Pfister, S. X., Markkanen, E., Jiang, Y., Sarkar, S., Woodcock, M., Orlando, G., Mavrommati, I., Pai, C.-C., Zalmas, L.-P., Drobnitzky, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.015 · Cited by 300
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Wee1 kinase as a target for cancer therapy
Do, K., Doroshow, J. H., & Kummar, S. (2013) · Cell Cycle · doi:10.4161/cc.26062 · Cited by 273
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J. F., & Würdinger, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2537 · Cited by 249
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., & Meyn, R. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0650 · Cited by 237
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., Hirsch, H. A., Feldman, I., Benita, Y., Toniatti, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0025 · Cited by 172
Self-citationThe wee1 protein kinase is required for radiation-induced mitotic delay
Rowley, R., Hudson, J. D., & Young, P. G. (1992) · Nature · doi:10.1038/356353a0 · Cited by 150
Linden, A. A. V., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L. A., Korch, C. T., Reigan, P., & Porter, C. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0424 · Cited by 130
Dose-finding in phase I clinical trials based on toxicity probability intervals
Ji, Y., Li, Y., & Bekele, B. N. (2007) · Clinical Trials · doi:10.1177/1740774507079442 · Cited by 130
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
Self-citationMK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Kreahling, J. M., Gemmer, J. Y., Reed, D. R., Letson, D. G., Bui, M. M., & Altiok, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0529 · Cited by 125
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
PosthumaDeBoer, J., Würdinger, T., Graat, H. C. A., van Beusechem, V. W., Helder, M. N., van Royen, B. J., & Kaspers, G. J. L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-156 · Cited by 121
Sarcar, B., Kahali, S., Prabhu, A. H., Shumway, S. D., Xu, Y., Demuth, T., & Chinnaiyan, P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0469 · Cited by 121
Self-citationCarrassa, L., Chilà, R., Lupi, M., Ricci, F., Celenza, C., Mazzoletti, M., Broggini, M., & Damia, G. L. M. (2012) · Cell Cycle · doi:10.4161/cc.20899 · Cited by 113
Leijen, S., Beijnen, J. H., & Schellens, J. H. M. (2010) · Current Clinical Pharmacology · doi:10.2174/157488410791498824 · Cited by 112
Self-citationChk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Davies, K. D., Cable, P. L., Garrus, J. E., Sullivan, F. X., von Carlowitz, I., Huérou, Y. L., Wallace, E. M., Woessner, R. D., & Gross, S. D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17673 · Cited by 89
Guertin, A. D., Martin, M. M., Roberts, B. S., Hurd, M. S., Qu, X., Miselis, N. R., Liu, Y., Li, J., Feldman, I., Benita, Y., et al. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-45 · Cited by 87
Self-citationHamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1894 · Cited by 84
Chaudhuri, L., Vincelette, N. D., Koh, B. D., Naylor, R. M., Flatten, K. S., Peterson, K. L., McNally, A., Gojo, I., Karp, J. E., Mesa, R. A., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.093187 · Cited by 80
Self-citationMizuarai, S., Yamanaka, K., Itadani, H., Arai, T., Nishibata, T., Hirai, H., & Kotani, H. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-34 · Cited by 72
Aarts, M., Bajrami, I., Herrera-Abreu, M. T., Elliott, R. J. R., Brough, R., Ashworth, A., Lord, C. J., & Turner, N. C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0845 · Cited by 63
WEE1 inhibition and genomic instability in cancer
Vriend, L. E. M., Hamer, P. C. D. W., Noorden, C. J. F. V., & Würdinger, T. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.002 · Cited by 57
Weisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., Nelson, E. A., Cowens, K. B., Christie, A. L., Mitsiades, C. S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.149 · Cited by 53
Xu, Y., Fang, W., Zeng, W., Leijen, S., & Woolf, E. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6440-6 · Cited by 38
Self-citation
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Self-citationA WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Ghelli Luserna di Rorà, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00959-2 · Cited by 314
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Metadata
- Authors
- Leijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., Freshwater, T., Shumway, S., Liang, L. W., Oza, A. M., Schellens, J. H. M., & Shapiro, G. I.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-12-20
- Volume
- 34
- Issue
- 36
- Pages
- 4371-4380
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2507880355
- Cited by
- 264
- References
- 38
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.